| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017042221 |
| P356 | DOI | 10.1038/LEU.2011.253 |
| P932 | PMC publication ID | 3306137 |
| P698 | PubMed publication ID | 21912393 |
| P5875 | ResearchGate publication ID | 51632498 |
| P50 | author | Ayalew Tefferi | Q66370740 |
| P2093 | author name string | A Pardanani | |
| T L Lasho | |||
| C M Finke | |||
| R A Knudson | |||
| N H Sulai | |||
| R F McClure | |||
| T Jimma | |||
| P2860 | cites work | The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 |
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Q24605258 | ||
| Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia | Q82464040 | ||
| p53 lesions in leukemic transformation | Q83352019 | ||
| Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms | Q95779600 | ||
| Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Q27687464 | ||
| Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor | Q27851558 | ||
| Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia | Q27851562 | ||
| IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. | Q27851565 | ||
| Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value | Q27851569 | ||
| IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status | Q27851581 | ||
| The prognostic significance of IDH2 mutations in AML depends on the location of the mutation | Q27851649 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Q29615366 | ||
| Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha | Q29619709 | ||
| Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients | Q33392291 | ||
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 | ||
| IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q33897586 | ||
| Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies | Q34158356 | ||
| IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. | Q34562170 | ||
| Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation | Q34755642 | ||
| DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms | Q36267848 | ||
| Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates | Q36303456 | ||
| Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal | Q37170349 | ||
| The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. | Q40463923 | ||
| Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations | Q42141882 | ||
| IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia | Q42878947 | ||
| LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations | Q42931701 | ||
| The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status | Q42962021 | ||
| Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group | Q42972388 | ||
| IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication | Q43010371 | ||
| Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). | Q43059179 | ||
| IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. | Q43089505 | ||
| Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms | Q43106526 | ||
| Taxing sugar-sweetened beverages | Q43180928 | ||
| MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 | ||
| Risk factors for leukemic transformation in patients with primary myelofibrosis | Q46650489 | ||
| Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. | Q51761197 | ||
| JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. | Q53185401 | ||
| Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. | Q54426186 | ||
| Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. | Q54594035 | ||
| IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis | Q58023817 | ||
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | Q61050093 | ||
| Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival | Q80542642 | ||
| Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases | Q80607021 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| collaboration | Q1145523 | ||
| myelofibrosis | Q1752571 | ||
| chronic idiopathic myelofibrosis | Q3857106 | ||
| P304 | page(s) | 475-480 | |
| P577 | publication date | 2011-09-13 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F | |
| P478 | volume | 26 |
| Q64098860 | -mutated acute myeloid leukemia: comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases |
| Q38018908 | Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors |
| Q89940664 | Allogeneic hematopoietic stem-cell transplantation for myelofibrosis |
| Q38174781 | Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? |
| Q33558154 | Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase |
| Q27852820 | CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients |
| Q29998841 | CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons |
| Q43405916 | Clinical significance of genetic aberrations in secondary acute myeloid leukemia |
| Q42361243 | Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis |
| Q38187675 | Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. |
| Q34661033 | DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies |
| Q27851680 | Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients |
| Q37968529 | Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms |
| Q33413428 | Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients |
| Q47209528 | Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. |
| Q38543775 | Emerging drugs for the treatment of myelofibrosis |
| Q38025160 | Emerging targeted therapies in myelofibrosis |
| Q39869997 | Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group |
| Q60929073 | Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy |
| Q26766319 | Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms |
| Q58010082 | Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm |
| Q91286849 | Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers |
| Q35995222 | Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome |
| Q38066786 | Genetic and epigenetic alterations of myeloproliferative disorders |
| Q38159973 | Genetic basis of MPN: Beyond JAK2-V617F. |
| Q26823651 | Genetics of myeloproliferative neoplasms |
| Q93085740 | Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019 |
| Q44718113 | IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension |
| Q38785528 | IDH mutations in cancer and progress toward development of targeted therapeutics |
| Q48595265 | IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes |
| Q24561928 | IDH1 and IDH2 mutations in gliomas |
| Q41665045 | Identification of potential therapeutic target genes and miRNAs for primary myelofibrosis with microarray analysis |
| Q34348505 | Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing |
| Q38133721 | Isocitrate dehydrogenase mutations in leukemia |
| Q49659982 | JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. |
| Q57796672 | Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations |
| Q39232415 | Management of myelofibrosis: JAK inhibition and beyond |
| Q38050756 | Molecular biology of Philadelphia-negative myeloproliferative neoplasms |
| Q44429606 | Mutations and prognosis in primary myelofibrosis |
| Q50072000 | Mutations in myeloproliferative neoplasms - their significance and clinical use. |
| Q90068705 | Myelofibrosis in 2019: moving beyond JAK2 inhibition |
| Q37548944 | Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes |
| Q27853094 | Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations |
| Q36512816 | One thousand patients with primary myelofibrosis: the mayo clinic experience |
| Q52668513 | Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. |
| Q37956603 | Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management |
| Q50462637 | Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management |
| Q39015300 | Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management |
| Q38926804 | Prognosis of Primary Myelofibrosis in the Genomic Era |
| Q33769072 | Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis |
| Q26738514 | Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned |
| Q37432049 | Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype |
| Q64092506 | State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 |
| Q34037065 | Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study |
| Q38102668 | TET proteins: on the frenetic hunt for new cytosine modifications. |
| Q42137322 | TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms |
| Q39482201 | Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms |
| Q89776742 | Targeted deep sequencing in polycythemia vera and essential thrombocythemia |
| Q36364763 | The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis |
| Q38121089 | The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms |
| Q38683077 | The evolution and clinical relevance of prognostic classification systems in myelofibrosis |
| Q37061554 | The future of epigenetic therapy in solid tumours--lessons from the past. |
| Q90260883 | The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia |
| Q34033164 | The role of mutations in epigenetic regulators in myeloid malignancies |
| Q39117766 | The role of the extracellular matrix in primary myelofibrosis |
| Q45961967 | U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. |
| Q36832167 | What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer |
| Q36788229 | What do we know about IDH1/2 mutations so far, and how do we use it? |
| Q86638414 | [Isocitrate dehydrogenase mutation in acute myeloid leukemia] |
Search more.